Clinical Trial Update: Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes [Phase 3]

View source ↗

Summary

Phase 3 trial comparing rivaroxaban-based antithrombotic strategy to antiplatelet strategy after transcatheter aortic valve replacement; the study is terminated…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transcatheter Aortic Valve Replacement

Drugs mentioned

• antiplatelet-based strategy
• rivaroxaban-based antithrombotic strategy (rivaroxaban)

Snippet

Sponsor: Bayer | Conditions: Transcatheter Aortic Valve Replacement | Phase 3 | Status: TERMINATED | Results posted: 2020-01-13